Citalopram - A review of pharmacological and clinical effects

Journal of Psychiatry and Neuroscience

Volumn 25, Issue 3, 2000, Pages 241-254

  Bezchlibnyk Butler, Kalyna ^a,b   Aleksic, Ivana ^c   Kennedy, Sidney H ^a  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c CAMH ^*  (United States)

Author keywords

Antidepressive agents; Citalopram; Drug interactions; Pharmacokinetics; Pharmacology; Serotonin uptake inhibitors

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; CYTOCHROME P450; HISTAMINE H2 RECEPTOR ANTAGONIST; ITRACONAZOLE; KETOCONAZOLE; MACROLIDE; MONOAMINE OXIDASE INHIBITOR; N TERT BUTYL 3 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL] 2 PHENYLPROPIONAMIDE; NEFAZODONE; NEUROLEPTIC AGENT; OMEPRAZOLE; RECEPTOR; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

AGE; CLINICAL TRIAL; DEPRESSION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; KIDNEY DISEASE; LIVER DYSFUNCTION; NONHUMAN; REVIEW; SEROTONIN SYNDROME; SEROTONIN UPTAKE; SEX;

AGED; CHILD; CHILD, PRESCHOOL; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DRUG INTERACTIONS; HUMANS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 0033898371     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. CANMAT Depression Working Group. Guidelines for the diagnosis and pharmacological treatment of depression. 1st edition. Toronto (ON): CANMAT; 1998. p. 16-22.
2. Parikh SV, Lesage AD, Kennedy SH, Geering PN. Depression in Ontario: undertreatment and factors related to antidepressant use. J Affect Disord 1999;52:67-76.
3. Lepine JP, Gastpar M, Mendlewicz J, Tylee A. Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol 1997;12:19-29.
4. Maddox JC, Levi M, Thompson C. The compliance with antidepressants in general practice. J Psychopharmacol 1994;8:48-53.
5. Rochat B, Amey M, Baumann P. Analysis of enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography. Ther Drug Monit 1945;17:273-9.
6. Hyttel J, Arnt J, Sanchez C. The pharmacology of citalopram. Rev Contemp Pharmacother 1995;6:271-85.
7. Baumann P, Larsen F. The pharmacokinetics of citalopram. Rev Contemp Pharmacother 1995;6:287-95.
8. 1A receptors. Eur J Pharmacol 1994;260:243-6.
9. Moret C, Briley M. Effects of acute and repeated administration of citalopram on extracellular levels of serotonin in rat brain. Eur J Pharmacol 1996;295:189-97.
10. Auerbach SB, Hjorth S. Effect of chronic administration of the selective serotonin (5-HT) uptake inhibitor citalopram on extracellular 5-HT and apparent autoreceptor sensitivity in rat forebrain in vivo. Naunyn Schmiedebergs Arch Pharmacol 1995;352:597-606.
11. Hyttel J. Citalopram-pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuropsychopharmacol Biol Psychiatry 1982;6:277-95.
12. Hyttel J, Overo KF, Arnt J. Biochemical effects and drug levels in rats after long-term treatment with the specific 5-HT uptake inhibitor, citalopram. Psychopharmacology 1984;83:20-7.
13. Milne RJ, Goa KL. Citalopram: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 1991;41:450-77.
14. 1A receptors and antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 1994;18:563-74.
15. 1A receptor antagonists increase the activity of serotonergic cells in the dorsal raphe nucleus in rats treated acutely or chronically with citalopram. Naunyn Schmiedebergs Arch Pharmacol 1995;352:157-65.
16. 1A receptor antagonist (S)-UH-301 augments the increase in extracellular concentrations of 5-HT in the frontal cortex produced by both acute and chronic treatment with citalopram. Naunyn Schmiedebergs Arch Pharmacol 1996;353:630-40.
17. Richelson E, Pfenning M. Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake. Eur J Pharmacol 1984;104:277-86.
18. 2 receptors and uptake sites in the neocortex of the rhesus monkey. J Comp Neurol 1989;280:27-42.
19. 1H] citalopram as markers of the human brain 5-HT uptake site: a comparison study. J Neurol Transm Gen Sect 1994;97:27-40.
20. Lopresti B, Holt D, Price JC, Mathis CA, Smith G, Kirshner M, et al. Estimation of serotonin reuptake transporter occupancy using citalopram to block C-11-[+]-McN5652 binding. 37th Annual Meeting of the American College of Neuropharmacology. San Juan, Puerto Rico. December 1998.
21. Noble S, Benfield P, Citalopram: A review of its pharmacology, clinical efficacy and tolerability in the treatment of depression. CNS Drugs 1997;8:410-31.
22. Rochat B, Amey M, Gillet M, Baumann P. Identification of three cytochrome P450 isoenzymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics 1997;7:1-10.
23. Rochat B, Kosel M, Boss G, Testa B, Gillet M, Baumann P. Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Biochem Pharmacol 1998;56:15-23.
24. Montgomery SA, Rasmussen JGC, Lyby K, Connor P, Tanghoj P. Dose response relationship of citalopram mg, citalopram 40 mg and placebo in the treatment of moderate and severe depression. Int Clin Psychopharmacol 1992;6(Suppl 5):65-70.
25. Leinonen E, Lepola U, Koponen H, Kinnunen I. The effect of age and concomitant treatment with other psychoactive drugs on serum concentrations of citalopram measured with a nonenantioselective method. Ther Drug Monit 1996;18:111-7.
26. Lundbeck Canada Inc. Celexa (Citalopram HBr) Product Monograph. International Drug Index List. 1948.
27. Foglia JP, Pollock BG, Kirshner MA, Rosen I, Sweet R, Mulsant B. Plasma levels of citalopram enantiomers and metabolites in elderly patients. Psychopharmacol Bull 1997;33:109-12.
28. Joffe P, Larsen FS, Pedersen V, Ring-Larsen H, Aaes-Jorgensen T, Sidhu J. Single-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects. Eur J Clin Pharmacol 1998;54:237-42.
29. Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brosen K. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996;51:73-8.
30. C'ANMAT Depression Working Group. Guidelines for the diagnosis and pharmacological treatment of depression. 1st edition. Toronto (ON): CANMAT; 1998. p. 51-3.
31. Sproule BA, Naranjo CA, Bremneske KE, Hassan PC. Selective serotonin reuptake inhibitors and CNS drug interactions: a critical review of the evidence. Clin Pharmacokinet 1997;33:454-71.
32. Harvey AT, Preskorn SH. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part II. J Clin Psychopharmacol 1996;16:345-55.
33. Bondolfi G, Chautems C, Rochat B, Bertschy G, Baumann P. Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of fluvoxamine augmentation. Psychopharmacology 1996;128:421-5.
34. Baettig D, Bondolfi G, Montaldi S, Amey M, Baumann P. Tricyclic antidepressant plasma levels after augmentation with citalopram: a case study. Eur J Clin Pharmacol 1993;44:403-5.
35. Gram LF, Hansen MG, Sindrup SH, Brosen K, Poulsen JH, Aaes- Jorgensen T, et al. Citalopram: interaction studies with levomepromazine, imipramine and lithium. Ther Drug Monit 1993;15:18-24.
36. Labbate LA, Rubey RN. Citalopram-the latest FDA-approved SSRI antidepressant: pharmacology and potential uses. Int Drug Ther Newsl 1999;34:9-16.
37. Neuvonen PJ, Pohjola-Sintonen S, Tacke U, Vuori E. Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. Lancet 1993;342:1419.
38. Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 1996;31:444-69.
39. Laine K, Anttila M, Heinonen H, Helminen A, Huupponen R, Maki-Ikola O, et al. Lack of adverse interactions between concomitantly administered selegiline and citalopram. Clin Neuropharmacol 1997;20:419-33.
40. Syvalahti EK, Taiminen T, Saarijarvi S, Lehto H, Niemi H, Ahola V, et al. Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients. J Int Med Res 1997;25:24-32.
41. Leinonen E, Lepola U, Koponen H. Substituting carbamazepine with oxocarbazine increases citalopram levels. A report on two cases. Pharmacopsychiatry 1996;29:156-8.
42. Gelenberg AL, editor. Citalopram (Celexa): SSRI #5. Biol Ther Psychiatry Newsl 1998;21:41-2.
43. Priskorn M, Sidhu JS, Larsen F, Davis JD, Khan AZ, Rolan PE. Investigation of multiple dose citalopram on the pharmacokinetics and pharmacodynamics of racemic warfarin. Br J Clin Pharmacol 1997;44:199-202.
44. Taylor D, Ellison Z, Shaw LE, Wickham H, Murray R. Co- administration of citalopram and clozapine: effect on plasma clozapine levels. Int Clin Psychopharmacol 1998;13:19-21.
45. Spigset O, Adielsson G. Combined serotonin syndrome and hyponatraemia caused by a citalopram-buspirone interaction. Int Clin Psychopharmacol 1997;12:61-3.
46. Baldwin D, Johnson FN. Tolerability and safety of citalopram. Rev Contemp Pharmacother 1995;6:315-25.
47. Muldoon C. The safety and tolerability of citalopram. Int Clin Psychopharmacol 1996;11(Suppl 1):35-40.
48. Gottfries CG, Karlsson I, Nyth AL. Treatment of depression in elderly patients with and without dementia disorders. Int Clin Psychopharmacol 1992;6(Suppl 5):55-64.
49. Segraves RT. Antidepressant-induced sexual dysfunction. J Clin Psychiatry 1998;59(Suppl 4):48-54.
50. Berk M, Acton M. Citalopram-associated clitoral priapism: a case series. Int Clin Psychopharmacol 1997;12:121-2.
51. Bouwer CD, Harvey BH. Phasic craving for carbohydrate observed with citalopram. Int Clin Psychopharmacol 1996;11:273-8.
52. Barbey JT, Roose SP. SSRI safety in overdose. J Clin Psychiatry 1998;59(Suppl 15):42-8.
53. Personne M, Persson H, Sjoberg G. Citalopram toxicity. Lancet 1997;350:518-9.
54. Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Dial Psychiatry 1998;44:77-87.
55. Thompson C. Discontinuation of antidepressant therapy: merging complications and their relevance. J Clin Psychiatry 1998;59(10):541-8.
56. Spigset O, Carieborg L, Ohman R, Norstrom A. Excretion of citalopram in breast milk. Br J Clin Pharmacol 1997;44:295-8.
57. Thomsen PH. Child and adolescent obsessive-compulsive disorder treated with citalopram: findings from an open trial of 23 cases. J Child Adolesc Psychopharmacol 1997;7:157-66.
58. Rosenberg C, Damsbo N, Fuglum E Jacobsen LV, Horsgard S. Citalopram and imipramine in the treatment of depressive patients in general practice: a Nordic multicentre clinical study. Int Clin Psychopharmacol 1994;9(Suppl 1):41-8.
59. Gravem A, Amthor KF, Astrup C, Elgen K, Gjessing LR, Gunby B, et al. A double-blind comparison of citalopram (lu 10-171) and amitriptyline in depressed patients. Acta Psychiatr Scand 1987;75:478-86.
60. Danish University Antidepressant Group. Citalopram: clinical effect profile in comparison with clomipramine: a controlled multicentre study. Psychopharmacology 1986;90:131-8.
61. Haffmans PMJ, Timmerman L, Hoogduin CAL and the LUCIFER group. Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double- blind multicentre study. Int Clin Psychopharmacol 1996;11:157-64.
62. Patris M, Bouchard J-M, Bougerol T, Charbonnier J-F, Chevalier J-F, Clerc G, et al. Citalopram versus fluoxetine: a double-blind, controlled multicentre, phase III trial in patients with unipolar major depression treated in general practice. Int Clin Psychopharmacol 1996;11:129-36.
63. Ekselius L, Von Knorring L, Eberhard G. A double blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general practice. Int Clin Psychopharmacol 1997;12:323-31.
64. Montgomery SA, Pedersen V, Tanghoj P, Rasmussen C, Rioux P. The optimal dosing regime for citalopram-a meta-analysis of nine placebo controlled studies. Int Clin Psychopharmacol 1994; 9(Suppl 1):35-40.
65. Montgomery SA, Rasmussen JG, Tanghoj P. A 24-week study of 20 mg citalopram, 40 mg citalopram and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 1993;8:181-8.
66. Robert P, Montgomery SA. Citalopram in doses of 20-60 mg is effective in depression relapse prevention: a placebo-controlled 6 month study. Int Clin Psychopharmacol 1995;10(Suppl 1):29-35.
67. Baumann, P, Vil R, Souche A, Montaldi S, Baettig D, Lambert S, et al. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic and pharmacogenetic investigation. J Clin Psychopharmacol 1996;16:307-14.
68. Thorell LH, Kjellman B, Arned M, Lindwall-Sundel K, Walinder J, Wetterberg L. Light treatment of SAD in combination with citalopram or placebo with one year follow up [abstract]. 1st International Citalopram Conference. Madeira (Portugal): 1998.
69. Andersen G, Vestergaard K, Lauritzen L. Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke 1994;25:1099-104.
70. Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders: a Nordic multicentre study. Br J Psychiatry 1992;157:894-901.
71. Wade AC, Lepola U, Koponen J, Pedersen V, Pedersen T. The effect of citalopram in panic disorder. Br J Psychiatry 1997;170:549-53.
72. Bouwer C, Stein DJ. Use of the selective serotonin reuptake inhibitor citalopram in the treatment of generalized social phobia. J Affect Disord 1998;49:79-82.
73. Koponen H, Lepola U, Leinonen E, Jokinen R, Penttinen J, Turtonen J. Citalopram in the treatment of obsessive-compulsive disorder: an open pilot study. Acta Psychiatr Scand 1997;96:343-6.
74. Balldin J, Berggren U, Engel J, Eriksson M, Hard E, Soderpalm B. Effect of citalopram on alcohol intake in heavy drinkers. Alcohol Clin Exp Res 1994;18:1133-6.
75. Naranjo CA, Poulos CX, Bremner KE, Lanctot KL. Citalopram decreases desirability, liking and consumption of alcohol in alcohol dependent drinkers. Clin Pharmacol Ther 1992;51:729-39.
76. Sindrup SH, Bjerre U, Dejgaard A, Brosen K, Aaes-Jorgensen T, Gram LF. The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther 1992;52:547-52.
77. Andersen G Treatment of uncontrolled crying after stroke. Drugs Aging 1995;6:105-11.